VivoSim Labs (NASDAQ:VIVS – Get Free Report) and Repligen (NASDAQ:RGEN – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.
Earnings & Valuation
This table compares VivoSim Labs and Repligen”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VivoSim Labs | $112,000.00 | 21.18 | -$13.84 million | ($4.47) | -0.03 |
| Repligen | $738.26 million | 14.57 | $48.89 million | ($0.21) | -801.56 |
Repligen has higher revenue and earnings than VivoSim Labs. Repligen is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
VivoSim Labs has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Repligen has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for VivoSim Labs and Repligen, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VivoSim Labs | 1 | 0 | 0 | 0 | 1.00 |
| Repligen | 1 | 3 | 12 | 2 | 2.83 |
Repligen has a consensus price target of $178.57, suggesting a potential upside of 6.09%. Given Repligen’s stronger consensus rating and higher probable upside, analysts plainly believe Repligen is more favorable than VivoSim Labs.
Insider & Institutional Ownership
8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 1.0% of VivoSim Labs shares are held by company insiders. Comparatively, 0.6% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares VivoSim Labs and Repligen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VivoSim Labs | -11,016.07% | -612.23% | -177.02% |
| Repligen | -1.47% | 5.49% | 3.93% |
Summary
Repligen beats VivoSim Labs on 11 of the 15 factors compared between the two stocks.
About VivoSim Labs
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
About Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for VivoSim Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VivoSim Labs and related companies with MarketBeat.com's FREE daily email newsletter.
